Research programme: IAP inhibitors - Aegera Therapeutics

Drug Profile

Research programme: IAP inhibitors - Aegera Therapeutics

Alternative Names: AEG-40056; AEG-40057; AEG-40706; AEG-40730

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Aegera Therapeutics
  • Class Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 20 May 2016 No recent reports on development identified - Preclinical for Cancer in Canada (Parenteral)
  • 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
  • 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top